JANET DAKERS-BIDLE: Open Payments
NPI 1235368994 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$865 in 39 payments from 13 companies in 2025. Trend: 2023 $1,233 · 2024 $950 · 2025 $865
Food & beverage: $865
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $139 |
| Ardelyx, Inc. | 4 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $108 |
| ABBVIE INC. | 4 | $81 |
| Madrigal Pharmaceuticals | 3 | $78 |
| Intercept Pharmaceuticals, Inc. | 3 | $69 |
| Phathom Pharmaceuticals, Inc. | 5 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $56 |
| Janssen Biotech, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $39 |
Products named: IBSRELA, ENTYVIO, REZDIFFRA, OCALIVA, RINVOQ, VOQUEZNA, DUPIXENT, TREMFYA.
Industry payments across MD — which companies pay providers there.
